Aurisco Pharmaceutical (SHA:605116) received a registration certificate from China's National Medical Products Administration for its dolutegravir sodium tablets, according to a Shanghai bourse filing on Tuesday.
The drug is used for the treatment of human immunodeficiency virus (HIV) in combination with other antiretroviral drugs.
The pharmaceutical company invested 14.2 million yuan in the drug's research and development.